Novo Nordisk and AWS bring agentic AI into drug discovery
| Source: AI News (ainews.com)
Tags: Novo Nordisk, AWS, Amazon Bedrock, Claude, drug discovery, healthcare AI, agentic AI, pharmaceutical
Novo Nordisk names AWS its preferred cloud and AI partner, creating a London co-innovation hub where AWS engineers and pharma scientists work side-by-side — a partnership already demonstrating Claude 3.5 cutting clinical documentation time by over 90%, from 15 weeks to minutes.
Details
The deal goes well beyond typical cloud procurement. Novo Nordisk is embedding AWS engineers and AI specialists inside its London R&D facility, explicitly targeting a shorter path from drug target identification to first human dose. Amazon Bio Discovery — designed for computational biology — is the central technology for early drug research workflows.\n\nExisting deployment data is concrete: more than 25,000 Novo Nordisk employees use a generative AI platform built on Amazon Bedrock, covering 2,500+ chatbot use cases. One system processes 26,000+ prompts per month across 140,000 documents. A clinical documentation tool using Claude 3.5 via Bedrock reduced work that previously required 40–50 people over 15 weeks to a 3-person task taking minutes — with human review continuing.\n\nThe co-innovation hub model — cloud engineers embedded inside the pharma R&D facility rather than working remotely — represents a deeper integration pattern that major pharma companies are increasingly adopting. AWS is positioning this as a template for AI-accelerated drug discovery, not just infrastructure.